Gaming and Abuse of Orphan Drugs

Pattern of gaming the system by slicing and dicing indications so that drugs qualify for lucrative orphan status benefits and getting taxpayer subsidies for blockbuster drugs, says a veteran scientist in USA. Companies are intentionally exploiting the law by putting up an initial listing of only single narrow indication for an orphan drugs use, which is just enough to qualify for "orphan" drug designation. Under the terms of this act, companies can receive federal taxpayer subsidies of up to half a million dollars a year for up to four years per drug, large tax credits and waivers of marketing application fees that can cost more than $2 million. In addition, the Food and Drug Administration (FDA) can grant companies seven years of marketing exclusivity for an orphan drug to ensure they recoup the costs of research and development. When those financial incentives become sort of an investment opportunity to take advantage of the Orphan Drug Act. The review found that orphan drug spending in the United States totalled $15 billion in 2007 and $30 billion in 2013, an increase from 4.8 percent of total pharmaceutical spending to 8.9 percent. The current study projects orphan drug spending will remain fairly stable as a proportion of total drug spending. That stands in contrast to other published reports that estimate orphan drugs will account for 20 percent of worldwide spending on drugs (other than generics) by 2020.

  • Financial incentives
  • Recouping the costs of research and development for orphan drugs
  • Forecasts of amount to be spent on orphan drugs by 2020

Related Conference of Gaming and Abuse of Orphan Drugs

October 14-15, 2019

19th World Congress on Advances in Pharmaceutical Sciences

Seoul, South Korea
October 25-26, 2019

14th International Conference on Biopharma and Biotherapeutics

| Copenhagen, Denmark
October 23-24, 2019 | Copenhagen, Denmark

12th Pharma Congress

September 11-12, 2019

2nd Annual Pharmaceutical Biotechnology Congress

Singapore
November 11-12, 2019

20th Annual Pharma Middle East Congress

Renaissance Polat Istanbul Hotel | Istanbul, Turkey
November 18-19, 2019

European Congress on Nanomedicine and Pharmaceutical Nanotechnology

Prague, Czech Republic
November 18-19, 2019

European Conference on Pharmacovigilance & Drug Safety

Prague, Czech Republic
December 02-03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 23- 24, 2020

14 th World Drug Delivery Summit

| Dublin, Ireland
March 25-26, 2020

23rd Asia Pacific Pharma Congress

Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
August 26-27, 2020

33rdWorld Congress on Pharmacology

Barcelona, Spain
October 19-20, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Gaming and Abuse of Orphan Drugs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in